Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
Oncol Rep. 2021 Mar;45(3):835-845. doi: 10.3892/or.2021.7943. Epub 2021 Jan 19.
CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migratory abilities of tumor cells via various pathways. TIGIT, an inhibitory receptor, is mainly expressed on natural killer (NK), CD8+ T, CD4+ T and T regulatory (Treg) cells. CD155 transmits immune signals via interacting with the inhibitory checkpoint receptor TIGIT, thereby inhibiting the function of T and NK cells. Several preclinical studies have supported the use of TIGIT blockade as a monotherapy or combined with other immune checkpoint inhibitors for the treatment of advanced solid malignant tumors. The present review summarized the current knowledge on CD155/TIGIT and the lymphocyte‑mediated inhibitory mechanism of CD155/TIGIT. An in‑depth understanding of the role of CD155/TIGIT in tumors may aid to improve the application of immune checkpoint inhibitors in tumor therapy.
CD155/T 细胞免疫受体含有免疫球蛋白和 ITIM 结构域（TIGIT）是一种新型免疫检查点。CD155 是一种黏附分子，在肿瘤进展过程中上调，并通过多种途径促进肿瘤细胞的增殖和迁移能力。TIGIT 是一种抑制性受体，主要表达于自然杀伤（NK）细胞、CD8+T 细胞、CD4+T 细胞和调节性 T（Treg）细胞上。CD155 通过与抑制性检查点受体 TIGIT 相互作用传递免疫信号，从而抑制 T 细胞和 NK 细胞的功能。几项临床前研究支持将 TIGIT 阻断作为单一疗法或与其他免疫检查点抑制剂联合用于治疗晚期实体恶性肿瘤。本综述总结了 CD155/TIGIT 的最新知识和 CD155/TIGIT 介导的淋巴细胞抑制机制。深入了解 CD155/TIGIT 在肿瘤中的作用可能有助于改善免疫检查点抑制剂在肿瘤治疗中的应用。
